Cargando…
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná
OBJECTIVE: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. METHODS: The...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318841/ https://www.ncbi.nlm.nih.gov/pubmed/25638763 http://dx.doi.org/10.1016/j.bjhh.2014.11.008 |
_version_ | 1782355882078633984 |
---|---|
author | Padilha, Sergio Lunardon Souza, Emannuely Juliani dos Santos Matos, Marcela Coriolano Cruz Domino, Natália Ramos |
author_facet | Padilha, Sergio Lunardon Souza, Emannuely Juliani dos Santos Matos, Marcela Coriolano Cruz Domino, Natália Ramos |
author_sort | Padilha, Sergio Lunardon |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. METHODS: The overall survival and disease-free survival were statistically evaluated using the Kaplan–Meier method, the log-rank test and multivariate evaluation by Cox regression analysis. RESULTS: The study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 10(9)/L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good prognostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 10(9)/L (median survival: 23.6 months; p-value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288). CONCLUSION: Prognostic factors strongly influenced patient survival, as well as guided treatment. Moreover, these factors were consistent with the available literature adjusted for the population in question. |
format | Online Article Text |
id | pubmed-4318841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-43188412015-02-19 Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná Padilha, Sergio Lunardon Souza, Emannuely Juliani dos Santos Matos, Marcela Coriolano Cruz Domino, Natália Ramos Rev Bras Hematol Hemoter Original Article OBJECTIVE: The aim of this study was to analyze the prognostic factors correlated with survival of patients with acute myeloid leukemia at the Hospital de Clínicas, Universidade Federal do Paraná between 2003 and 2009, as well as to investigate the clinical and epidemiological profile. METHODS: The overall survival and disease-free survival were statistically evaluated using the Kaplan–Meier method, the log-rank test and multivariate evaluation by Cox regression analysis. RESULTS: The study population was predominantly younger than 60 years old (81,6%), had intermediate cytogenetic risk (40.8%), in first complete remission after induction chemotherapy (46.9%), with a white blood count at diagnosis of less than 30 × 10(9)/L (57.1%) and de novo acute myeloid leukemia (62.2%). Survival curves showed that better prognosis was related to age below 60 years (median:12,4 months; p-value = 0,2227; Odds Ratio = 0,6676), good prognostic cytogenetic markers (median: 97.7 months; p-value = 0.0037; Odds Ratio = 0.4239) and white blood cell count at diagnosis of less than 30 × 10(9)/L (median survival: 23.6 months; p-value = 0.0001; Odds Ratio = 0.3651). Regarding the French-American-British subgroups, the median overall survival was 23.5 months for M0, M1 and M2, 97.7 months for M3 and 7.4 months for M4, M5, M6, and M7 (p-value = 0.0288). CONCLUSION: Prognostic factors strongly influenced patient survival, as well as guided treatment. Moreover, these factors were consistent with the available literature adjusted for the population in question. Sociedade Brasileira de Hematologia e Hemoterapia 2015 2014-11-21 /pmc/articles/PMC4318841/ /pubmed/25638763 http://dx.doi.org/10.1016/j.bjhh.2014.11.008 Text en © 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved. |
spellingShingle | Original Article Padilha, Sergio Lunardon Souza, Emannuely Juliani dos Santos Matos, Marcela Coriolano Cruz Domino, Natália Ramos Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title | Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title_full | Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title_fullStr | Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title_full_unstemmed | Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title_short | Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná |
title_sort | acute myeloid leukemia: survival analysis of patients at a university hospital of paraná |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318841/ https://www.ncbi.nlm.nih.gov/pubmed/25638763 http://dx.doi.org/10.1016/j.bjhh.2014.11.008 |
work_keys_str_mv | AT padilhasergiolunardon acutemyeloidleukemiasurvivalanalysisofpatientsatauniversityhospitalofparana AT souzaemannuelyjulianidossantos acutemyeloidleukemiasurvivalanalysisofpatientsatauniversityhospitalofparana AT matosmarcelacoriolanocruz acutemyeloidleukemiasurvivalanalysisofpatientsatauniversityhospitalofparana AT dominonataliaramos acutemyeloidleukemiasurvivalanalysisofpatientsatauniversityhospitalofparana |